Gritstone Bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Gritstone Bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 --
— 評估一線轉移性微衛星穩定性結直腸癌(MSS-CRC)的GRANITE(個性化新抗原疫苗)的隨機2期研究的初步數據中觀察到良好的無進展存活率(PFS)趨勢;成熟的PFS數據預計將於2024年第三季度公佈——
-- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE (tumor antigen identification platform that was recently enhanced using large language models) highlight Gritstone's leadership in neoantigen-directed cancer vaccine field --
-- 自然醫學 SLATE(現成的新抗原疫苗)的1期研究的發佈以及AACR提出的對EDGE(腫瘤抗原識別平台,最近使用大型語言模型進行了增強)的改進突顯了Gritstone在新抗原導向癌症疫苗領域的領導地位——
-- Latest data from Phase 1 CORAL-CEPI study highlights the durability and potential broad utility of Gritstone's novel self-amplifying mRNA (samRNA) "Spike-plus" COVID-19 vaccine --
— CORAL-CEPI 第 1 期研究的最新數據凸顯了 Gritstone 的新型自擴增 mRNA (samRNA) “Spike-Plus” COVID-19 疫苗的耐久性和潛在的廣泛用途 —
-- Recent financing resulted in $32.5 million in gross proceeds to Gritstone in April 2024 --
— 最近的融資使Gritstone在2024年4月獲得了3,250萬美元的總收益——
-- Gritstone to host conference call today at 4:30pm ET --
— Gritstone 將於美國東部時間今天下午 4:30 主持電話會議 —
EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today reported financial results for the first quarter ended March 31, 2024 and provided recent corporate and clinical updates.
加利福尼亞州埃默裏維爾,2024年5月9日(GLOBE NEWSWIRE)——致力於開發世界上最有效的疫苗的臨床階段生物技術公司Gritstone bio, Inc.(納斯達克股票代碼:GRTS)今天公佈了截至2024年3月31日的第一季度財務業績,並提供了最新的公司和臨床最新情況。
"The preliminary Phase 2 data we recently shared are very promising as they suggest that GRANITE is potentially driving benefit in metastatic CRC patients and that our objective of unlocking immunologically 'cold' tumors to the benefits of immunotherapy may be within reach," said Andrew Allen, MD, PhD, Co-founder, President & CEO of Gritstone bio. "The emerging trend in progression-free survival, that we anticipate will strengthen as data mature, is particularly encouraging as it puts us in a strong position to potentially engage regulators later this year regarding a Phase 3 study for this common and difficult to treat disease. If successful, we see great potential for GRANITE to expand the scope of immunotherapy and bring meaningful clinical benefit to patients with metastatic CRC as well as other 'cold' tumors."
Gritstone bio聯合創始人、總裁兼首席執行官安德魯·艾倫說:“我們最近分享的第二階段初步數據非常有希望,因爲它們表明GRANITE有可能推動轉移性結直腸癌患者的受益,而我們解鎖免疫學'冷'腫瘤受益的目標可能觸手可及。”“我們預計,隨着數據的成熟,無進展存活率的新趨勢將得到加強,這尤其令人鼓舞,因爲這使我們處於有利地位,有可能在今年晚些時候就針對這種常見且難以治療的疾病的三期研究與監管機構接觸。如果成功,我們認爲GRANITE有很大的潛力擴大免疫治療的範圍,爲轉移性結直腸癌和其他'感冒'腫瘤的患者帶來有意義的臨床益處。”
Dr. Allen added, "The progress in, and recognition of our other programs and capabilities is also encouraging. The recent paper in Nature Medicine highlights the scientific rigor with which we built our SLATE platform, describes the discovery of a previously unknown hierarchy of neoantigen immunodominance, and underscores the promise for the ongoing collaboration with Dr. Rosenberg of the NCI to evaluate our SLATE-KRAS vaccine in combination with an autologous T cell therapy. We also continue to push the boundaries of neoantigen identification with EDGE, our powerful AI-driven platform, that can now predict presentation of HLA Class I neoantigens with what we believe to be field-leading accuracy."
艾倫博士補充說:“我們的其他項目和能力的進展和認可也令人鼓舞。最近的報紙在 自然醫學 重點介紹了我們構建SLATE平台時所遵循的科學嚴謹性,描述了以前未知的新抗原免疫優勢層次結構的發現,並強調了與NCI的羅森伯格博士持續合作評估我們的SLATE-KRAS疫苗與自體T細胞療法聯合使用的前景。我們還繼續利用我們強大的人工智能驅動平台EDGE突破新抗原鑑定的界限,該平台現在可以預測HLA I類新抗原的呈現,我們認爲其精度領先於領域。”
Corporate Updates
企業最新消息
- In April 2024, Gritstone completed an underwritten public offering resulting in gross proceeds of $32.5 million.
- In April 2024, Gritstone appointed Stephen Webster to its Board of Directors. A veteran finance executive with over 30 years in the biotechnology industry, Mr. Webster has held several key roles and been involved in multiple strategic transactions. Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
- 2024年4月,Gritstone完成了承銷的公開募股,總收益爲3,250萬美元。
- 2024 年 4 月,Gritstone 任命斯蒂芬·韋伯斯特爲董事會成員。韋伯斯特先生是一位在生物技術行業擁有30多年的資深財務主管,曾擔任過多個關鍵職務,並參與了多項戰略交易。韋伯斯特先生從2014年7月起擔任Spark Therapeutics的首席財務官,直到2019年12月羅氏以43億美元的價格收購了Spark Therapeutics。
Clinical Program Updates
Tumor-Specific Neoantigen Oncology Programs (GRANITE and SLATE)
GRANITE – Personalized neoantigen vaccine program
SLATE – "Off-the-shelf" neoantigen vaccine program
臨床計劃更新
腫瘤特異性新抗原腫瘤學項目(GRANITE 和 SLATE)
GRANITE — 個性化新抗原疫苗計劃
SLATE — “現成的” 新抗原疫苗計劃
-
Preliminary results (n = 67) from the randomized Phase 2 study evaluating GRANITE as a front-line maintenance therapy in metastatic microsatellite-stable colorectal cancer (MSS-CRC) demonstrated a favorable trend in progression-free survival (PFS). Long-term circulating tumor DNA (ctDNA) data align with PFS trend and favor GRANITE vs. control patients.
- Trend of extended PFS in GRANITE-treated vs. control patients, with greatest difference observed in high-risk group1 where clinical data are more mature.
- Hazard ratio of 0.82 (18% relative risk reduction of progression or death with GRANITE vs. control) in the overall population, where clinical data are less mature ([95% CI, 0.34-1.67]; 62% censored)
- Hazard ratio of 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group1, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored)
- Trend of extended PFS in GRANITE-treated vs. control patients, with greatest difference observed in high-risk group1 where clinical data are more mature.
- 評估GRANITE作爲轉移性微衛星穩定性結直腸癌(MSS-CRC)的一線維持療法的隨機2期研究的初步結果(n = 67)顯示,無進展生存(PFS)呈現出良好的趨勢。長期循環腫瘤DNA(ctDNA)數據符合PFS趨勢,與對照組患者相比,有利於GRANITE。
- 花崗岩治療患者與對照組患者延長 PFS 的趨勢,在高風險組中觀察到的差異最大1 臨床數據更加成熟的地方。
- 臨床數據不太成熟([95% 置信區間,0.34-1.67];62% 已審查)在總人群中,危害率爲0.82(GRANITE進展或死亡的相對風險與對照組相比降低 18%)
- 高危人群的危害比爲 0.52(GRANITE 與對照組相比,GRANITE 進展或死亡的相對風險降低 48%)1,臨床數據更爲成熟([95% 置信區間,0.15-1.38];44% 已審查)
- 花崗岩治療患者與對照組患者延長 PFS 的趨勢,在高風險組中觀察到的差異最大1 臨床數據更加成熟的地方。
1High-risk subgroup defined as baseline ctDNA above the median value (2%) for the control group (ctDNA quantified as mean variant allele frequency [VAF] at time of study randomization).
1高風險亞組定義爲高於對照組中值(2%)的基線 ctDNA(研究隨機分組時 ctDNA 量化爲平均變異等位基因頻率 [VAF])。
- Long-term ctDNA data align with PFS trend and favor GRANITE-treated vs. control patients
- Analysis in the high-risk group1 showed that between first blood draw (time of randomization) and last blood draw (most recent study visit), ctDNA shifted from high (>2% VAF) to low (≤2% VAF) in 56% (9/16) of GRANITE patients vs 22% (2/9) of control patients. Progressive disease was observed in 44% (7/16) vs 78% (7/9), respectively, within this group.
- Analysis in low-risk group (ctDNA negative group) showed sustained ctDNA negativity was observed in 67% (6/9) GRANITE recipients vs 38% (3/8) control patients. PD observed in 11% (1/9) and 38% (3/8) of these patients, respectively.
- Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
- 長期 ctDNA 數據符合 PFS 趨勢,與對照組患者相比,接受花崗岩治療的患者更受青睞
- 高風險人群分析1 表明,在第一次抽血(隨機分組時間)和最後一次抽血(最近的研究訪問)之間,56%(9/16)的GRANITE患者的ctDNA從高(> 2%VAF)變爲低(≤2%VAF),而對照組患者爲22%(2/9)。在該組中,分別有44%(7/16)和78%(7/9)的患者觀察到進行性疾病。
- 對低風險組(ctDNA陰性組)的分析顯示,在67%(6/9)GRANITE接受者中觀察到持續的ctDNA陰性,而對照組的患者爲38%(3/8)。在這些患者中,分別有11%(1/9)和38%(3/8)的患者觀察到PD。
- Gritstone預計將在2024年第三季度分享成熟的PFS數據和其他長期ctDNA數據。
-
In April 2024, Gritstone presented an update on its state-of-the-art neoantigen prediction platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.EDGE now predicts HLA Class I presentation, associated with CD8+ T cell induction, with >80% accuracy, a performance level that Gritstone believes to be leading the field. Gritstone is also advancing EDGE-II, a new model that has achieved superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models. The improvements leverage advances in protein large language models and in-house immunopeptidomics.
-
In March 2024, Nature Medicine published a paper detailing the development of our "off-the-shelf" neoantigen platform, SLATE. The paper described a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a "pure" KRAS-directed vaccine candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study.
-
The clinical trial collaboration with the National Cancer Institute (NCI) to evaluate an autologous mutant KRAS-directed TCR-T cell therapy in combination with SLATE-KRAS, Gritstone's KRAS-directed "off the shelf" vaccine candidate, is ongoing. The study is led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI's Center for Cancer Research and builds into the growing interest in combining tumor-antigen specific cell therapy with matched vaccines. The IND was cleared by the U.S. Food and Drug Administration (FDA) in October 2023.
- 2024年4月,Gritstone在加利福尼亞州聖地亞哥舉行的2024年美國癌症研究協會(AACR)年會上介紹了其最先進的新抗原預測平台EDGE的最新情況。EDGE現在預測與CD8+ T細胞誘導相關的HLA的I類表現,準確率超過80%,Gritstone認爲這一性能水平處於領先地位。Gritstone還在推進EDGE-II的發展,這是一種新模型,與公開的模型相比,它在HLA II類表現和CD4+免疫原性方面取得了優異的預測性能。這些改進利用了蛋白質大語言模型和內部免疫肽組學的進步。
- 2024年3月,《自然醫學》發表了一篇論文,詳細介紹了我們的 “現成的” 新抗原平台SLATE的開發。該論文描述了Gritstone在1期轉化研究中發現的腫瘤新抗原(包括KRAS)的新免疫優勢層次結構,並利用它開發了SLATE-KRAS,這是一種 “純” 的KRAS候選疫苗,在隨後的2期研究中表現出優於初始版本的免疫原性。
- 與美國國家癌症研究所(NCI)的臨床試驗合作正在進行中,該研究旨在評估一種自體突變體KRAS導向的TCR-T細胞療法與Gritstone針對KRAS的 “現成” 候選疫苗SLATE-KRAS聯合使用。該研究由NCI癌症研究中心外科主任史蒂芬·羅森伯格醫學博士、博士領導,這激發了人們對將腫瘤抗原特異性細胞療法與配套疫苗相結合的興趣與日俱增。該新藥於 2023 年 10 月獲得美國食品藥品監督管理局 (FDA) 的批准。
Infectious Disease Programs
CORAL – Next-generation SARS-CoV-2 vaccine program that serves as proof-of-concept for Gritstone's samRNA platform and novel approach in infectious diseases.
傳染病項目
CORAL — 下一代SARS-CoV-2疫苗計劃,可作爲Gritstone的samRNA平台和傳染病新方法的概念驗證。
-
In February 2024, Gritstone announced that it plans to incorporate GMP-grade materials in the manufacture of its self-amplifying mRNA (samRNA) candidate, resulting in a delay of the CORAL Phase 2b study (the anticipated 10,000 subject, comparative Phase 2b study contracted by the Biomedical Advanced Research and Development Authority [BARDA]2). This decision is expected to increase the regulatory utility of the study. Gritstone is currently preparing to launch the study and will do so as soon as the company is able.
-
In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024. The results, which were from the Phase 1 CORAL-CEPI study in South Africa, reinforced previous findings showing induction of broad and durable immune responses through 12 months.
- 2024年2月,Gritstone宣佈計劃將GMP級材料納入其自放大mRNA(samRNA)候選物的製造中,這導致CORAL 2b期研究(預計爲10,000名受試者,由生物醫學高級研究與發展局 [BARDA] 簽約的2b期比較研究)延遲2)。預計這一決定將增加該研究的監管效用。Gritstone目前正準備啓動這項研究,並將儘快啓動這項研究。
- 2024 年 4 月,Gritstone 在 ESCMID Global 2024 上展示了一張海報,重點介紹了其 samRNA COVID-19 疫苗的耐久性和潛在的廣泛用途。這些結果來自南非CORAL-CEPI的1期研究,進一步證實了先前的發現,即在12個月內誘發廣泛而持久的免疫反應。
HIV – Collaboration with Gilead under Gilead's HIV Cure Program to research and develop vaccine-based HIV immunotherapy treatment
HIV — 在吉利德的HIV治療計劃下與吉利德合作,研究和開發基於疫苗的HIV免疫療法
-
The collaboration to research and develop a vaccine-based HIV immunotherapy treatment continues under Gilead's direction.
- 在吉利德的指導下,研究和開發基於疫苗的HIV免疫療法療法的合作仍在繼續。
First Quarter 2024 Financial Results
2024 年第一季度財務業績
-
Cash, cash equivalents, marketable securities and restricted cash were $52.8 million as of March 31, 2024, compared to $86.9 million as of December 31, 2023.
- 截至2024年3月31日,現金、現金等價物、有價證券和限制性現金爲5,280萬美元,而截至2023年12月31日爲8,690萬美元。
-
Research and development expenses were $33.0 million for the three months ended March 31, 2024 compared to $30.5 million for the three months ended March 31, 2023. The increase of $2.5 million was primarily attributable to a one-time severance charge and increases in facilities-related costs, offset by decreases in laboratory supplies, personnel-related costs and outside services.
-
General and administrative expenses were $8.5 million for the three months ended March 31, 2024 compared to $6.7 million for the three months ended March 31, 2023. The increase of $1.8 million was primarily attributable to increases in personnel-related expenses, facilities-related costs, outside services and a one-time severance charge.
-
Collaboration, license, and grant revenues were $1.7 million for the three months ended March 31, 2024. During the three months ended March 31, 2024, we recorded $0.4 million in grant revenue from the BARDA Contract, $1.0 million in grant revenue from CEPI, and $0.3 million in grant revenue from the Gates Foundation.
- 截至2024年3月31日的三個月,研發費用爲3,300萬美元,而截至2023年3月31日的三個月,研發費用爲3,050萬美元。增加250萬美元主要歸因於一次性離職費和設施相關費用的增加,但被實驗室用品、人事相關費用和外部服務的減少所抵消。
- 截至2024年3月31日的三個月,一般和管理費用爲850萬美元,而截至2023年3月31日的三個月爲670萬美元。增加180萬美元的主要原因是人事相關支出、設施相關費用、外部服務和一次性遣散費的增加。
- 截至2024年3月31日的三個月,合作、許可和補助金收入爲170萬美元。在截至2024年3月31日的三個月中,我們記錄了來自BARDA合同的40萬美元贈款收入,來自CEPI的100萬美元贈款收入以及來自蓋茨基金會的30萬美元贈款收入。
Conference Call & Webcast Details
A conference call and webcast will be held at 4:30pm ET today (May 9):
Conference call: 1-877-407-4018
Conference ID: 13746126
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa
電話會議和網絡直播詳情
電話會議和網絡直播將於美國東部時間今天(5月9日)下午 4:30 舉行:
電話會議:1-877-407-4018
會議 ID:13746126
網絡直播: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa
An archived replay will be accessible at https://ir.gritstonebio.com/investors/events for 30 days following the event.
存檔的重播可在以下網址獲取 https://ir.gritstonebio.com/investors/events 活動結束後的 30 天內。
2 This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00062. |
2 該項目得到了衛生與公共服務部、戰略準備和反應管理局、生物醫學高級研究與發展局(BARDA)的全部或部分聯邦資金支持,合同編號爲 75A50123C00062。 |
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world's most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
關於 Gritstone bio
Gritstone bio, Inc.(納斯達克股票代碼:GRTS)是一家臨床階段的生物技術公司,旨在開發世界上最有效的疫苗。我們利用我們的創新載體和有效載荷來訓練免疫系統的多個分支來攻擊關鍵疾病靶點。我們正在獨立地與我們的合作者一起推進治療和預防病毒性疾病和實體瘤的候選產品組合,以改善患者的預後並消除疾病。 www.gritstonebio.com
Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to our clinical and regulatory development plans for our product candidates; our expectations regarding the data to be derived in our ongoing and planned clinical trials; the timing of commencement of our future nonclinical studies, clinical trials and research and development programs; our ability to discover, develop and advance product candidates into, and successfully complete, clinical trials; and our plans and strategy regarding maintaining existing and entering into new collaborations and/or partnerships. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Annual Report on Form 10-K filed on March 5, 2024, our Form 10-Q filed on May 9, 2024, and any subsequent current reports filed with the Securities and Exchange Commission.
Gritstone 前瞻性陳述
本新聞稿包含前瞻性陳述,包括但不限於與我們的候選產品的臨床和監管開發計劃相關的陳述;我們對正在進行和計劃中的臨床試驗中得出的數據的期望;我們未來非臨床研究、臨床試驗和研發計劃的啓動時間;我們發現、開發和推進候選產品進入臨床試驗併成功完成臨床試驗的能力;以及我們關於維持現有和臨床試驗的計劃和戰略建立新的合作和/或夥伴關係。此類前瞻性陳述涉及重大風險和不確定性,可能導致Gritstone的研究和臨床開發計劃、未來結果、業績或成就與前瞻性陳述所表達或暗示的顯著差異。除其他外,此類風險和不確定性包括藥物開發過程中固有的不確定性,包括Gritstone項目的臨床開發階段、設計和進行臨床前和臨床試驗的過程、監管機構的批准程序、監管機構申報的時機、與製造藥品相關的挑戰、Gritstone成功建立、保護和捍衛其知識產權的能力以及其他可能影響現有現金爲運營提供資金的問題。Gritstone沒有義務更新或修改任何前瞻性陳述。有關可能導致實際業績與這些前瞻性陳述中表達的結果不同的風險和不確定性以及與公司總體業務相關的風險的進一步描述,請參閱Gritstone於2024年3月5日提交的最新10-K表年度報告、2024年5月9日提交的10-Q表以及隨後向美國證券交易委員會提交的任何最新報告。
This press release concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
本新聞稿涉及正在進行臨床研究且尚未獲得美國食品藥品監督管理局批准上市的藥物。目前,根據聯邦法律,它們僅限於研究用途,對於其調查目的的安全性或有效性,不作任何陳述。
Gritstone Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com
Gritstone 聯繫方式
投資者:
喬治 E. 麥克杜格爾
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
媒體:
丹·佈德威克
1AB
(973) 271-6085
dan@1abmedia.com
Gritstone bio, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(In thousands)
Gritstone bio, Inc.
簡明合併資產負債表(未經審計)
(以千計)
March 31, 2024 | December 31, 2023 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 42,395 | $ | 62,986 | |||
Marketable securities | 3,908 | 16,288 | |||||
Restricted cash | 1,247 | 2,299 | |||||
Prepaid expenses and other current assets | 4,303 | 5,862 | |||||
Total current assets | 51,853 | 87,435 | |||||
Long-term restricted cash | 5,290 | 5,290 | |||||
Property and equipment, net | 14,088 | 17,281 | |||||
Lease right-of-use assets | 65,057 | 66,839 | |||||
Deposits and other long-term assets | 924 | 924 | |||||
Total assets | $ | 137,212 | $ | 177,769 | |||
Liabilities and stockholders' equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 7,248 | $ | 3,819 | |||
Accrued compensation | 4,340 | 9,357 | |||||
Accrued liabilities | 2,141 | 1,213 | |||||
Accrued research and development expenses | 4,045 | 3,696 | |||||
Lease liabilities, current portion | 6,811 | 6,904 | |||||
Deferred revenue, current portion | 1,285 | 2,350 | |||||
Total current liabilities | 25,870 | 27,339 | |||||
Other liabilities, noncurrent | 907 | 709 | |||||
Lease liabilities, net of current portion | 56,141 | 57,727 | |||||
Debt, noncurrent | 40,330 | 40,144 | |||||
Total liabilities | 123,248 | 125,919 | |||||
Stockholders' equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 22 | 22 | |||||
Additional paid-in capital | 713,889 | 711,386 | |||||
Accumulated other comprehensive (loss) gain | (1) | 3 | |||||
Accumulated deficit | (699,946) | (659,561) | |||||
Total stockholders' equity | 13,964 | 51,850 | |||||
Total liabilities and stockholders' equity | $ | 137,212 | $ | 177,769 |
2024年3月31日 | 2023年12月31日 | ||||||
資產 | |||||||
流動資產: | |||||||
現金和現金等價物 | $ | 42,395 | $ | 62,986 | |||
有價證券 | 3,908 | 16,288 | |||||
受限制的現金 | 1,247 | 2,299 | |||||
預付費用和其他流動資產 | 4,303 | 5,862 | |||||
流動資產總額 | 51,853 | 87,435 | |||||
長期限制性現金 | 5,290 | 5,290 | |||||
財產和設備,淨額 | 14,088 | 17,281 | |||||
租賃使用權資產 | 65,057 | 66,839 | |||||
存款和其他長期資產 | 924 | 924 | |||||
總資產 | $ | 137,212 | $ | 177,769 | |||
負債和股東權益 | |||||||
流動負債: | |||||||
應付賬款 | $ | 7,248 | $ | 3,819 | |||
應計補償 | 4,340 | 9,357 | |||||
應計負債 | 2,141 | 1,213 | |||||
應計的研發費用 | 4,045 | 3,696 | |||||
租賃負債,流動部分 | 6,811 | 6,904 | |||||
遞延收入,當期部分 | 1,285 | 2,350 | |||||
流動負債總額 | 25,870 | 27,339 | |||||
其他非流動負債 | 907 | 709 | |||||
租賃負債,扣除流動部分 | 56,141 | 57,727 | |||||
債務,非流動 | 40,330 | 40,144 | |||||
負債總額 | 123,248 | 125,919 | |||||
股東權益: | |||||||
優先股 | — | — | |||||
普通股 | 22 | 22 | |||||
額外的實收資本 | 713,889 | 711,386 | |||||
累計的其他綜合(虧損)收益 | (1) | 3 | |||||
累計赤字 | (699,946) | (659,561) | |||||
股東權益總額 | 13,964 | 51,850 | |||||
負債和股東權益總額 | $ | 137,212 | $ | 177,769 |
Gritstone bio, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(In thousands, except share and per share amounts)
Gritstone bio, Inc.
簡明合併運營報表和綜合虧損表(未經審計)
(以千計,股票和每股金額除外)
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Revenues: | ||||||||
Collaboration and license revenues | $ | 49 | $ | 542 | ||||
Grant revenues | 1,693 | 1,901 | ||||||
Total revenues | 1,742 | 2,443 | ||||||
Operating expenses: | ||||||||
Research and development | 33,041 | 30,514 | ||||||
General and administrative | 8,502 | 6,745 | ||||||
Total operating expenses | 41,543 | 37,259 | ||||||
Loss from operations | (39,801) | (34,816) | ||||||
Interest income | 712 | 1,678 | ||||||
Interest expense | (1,296) | (844) | ||||||
Net loss | (40,385) | (33,982) | ||||||
Other comprehensive loss: | ||||||||
Unrealized (loss) gain on marketable securities | (4) | 28 | ||||||
Comprehensive loss | $ | (40,389) | $ | (33,954) | ||||
Net loss per share, basic and diluted | $ | (0.34) | $ | (0.30) | ||||
Weighted-average number of shares used in computing net loss per share, basic and diluted | 118,391,224 | 114,423,000 |
截至3月31日的三個月 | ||||||||
2024 | 2023 | |||||||
收入: | ||||||||
合作和許可收入 | $ | 49 | $ | 542 | ||||
補助收入 | 1,693 | 1,901 | ||||||
總收入 | 1,742 | 2,443 | ||||||
運營費用: | ||||||||
研究和開發 | 33,041 | 30,514 | ||||||
一般和行政 | 8,502 | 6,745 | ||||||
運營費用總額 | 41,543 | 37,259 | ||||||
運營損失 | (39,801) | (34,816) | ||||||
利息收入 | 712 | 1,678 | ||||||
利息支出 | (1,296) | (844) | ||||||
淨虧損 | (40,385) | (33,982) | ||||||
其他綜合損失: | ||||||||
有價證券的未實現(虧損)收益 | (4) | 28 | ||||||
綜合損失 | $ | (40,389) | $ | (33,954) | ||||
基本和攤薄後的每股淨虧損 | $ | (0.34) | $ | (0.30) | ||||
用於計算基本和攤薄後每股淨虧損的加權平均股數 | 118,391,224 | 114,423,000 |
譯文內容由第三人軟體翻譯。